Shanghai Bio-heart (2185) Announces First Commercial Case of Iberis® RDN System in Switzerland

Bulletin Express

Oct 23

Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) in Switzerland. The procedure took place at the University Hospital Basel with no complications or adverse events reported, supported jointly by Biosensors International Group, Ltd. and AngioCare.

AngioCare and Biosensors have a strategic partnership covering multiple regions, including the European Union, the Asia–Pacific region, and Latin America, for the commercialization of the Iberis® RDN system. According to the announcement, this system is currently the only renal denervation product approved globally with both transradial (TRA) and transfemoral (TFA) approaches.

Biosensors is a Bermuda-incorporated company under the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (002382), operating worldwide with headquarters in Singapore and a European office in Morges, Switzerland.

The announcement also states that there is no guarantee Iberis® RDN system will be ultimately developed or marketed successfully, and investors are advised to exercise due care when dealing in the shares of Shanghai Bio-heart Biological Technology Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181625029"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181625029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181625029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181625029","market":"hk","top_or_hot":-1,"title":"Shanghai Bio-heart (2185) Announces First Commercial Case of Iberis® RDN System in Switzerland","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) in Switzerland. The procedure took place at the University Hospital Basel with no complications or adverse events reported, supported jointly by Biosensors International Group, Ltd. and AngioCare.</p>\n<p>AngioCare and Biosensors have a strategic partnership covering multiple regions, including the European Union, the Asia–Pacific region, and Latin America, for the commercialization of the Iberis® RDN system. According to the announcement, this system is currently the only renal denervation product approved globally with both transradial (TRA) and transfemoral (TFA) approaches.</p>\n<p>Biosensors is a Bermuda-incorporated company under the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (002382), operating worldwide with headquarters in Singapore and a European office in Morges, Switzerland.</p>\n<p>The announcement also states that there is no guarantee Iberis® RDN system will be ultimately developed or marketed successfully, and investors are advised to exercise due care when dealing in the shares of Shanghai Bio-heart Biological Technology Co., Ltd.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bio-heart (2185) Announces First Commercial Case of Iberis® RDN System in Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bio-heart (2185) Announces First Commercial Case of Iberis® RDN System in Switzerland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-23 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) in Switzerland. The procedure took place at the University Hospital Basel with no complications or adverse events reported, supported jointly by Biosensors International Group, Ltd. and AngioCare.</p>\n<p>AngioCare and Biosensors have a strategic partnership covering multiple regions, including the European Union, the Asia–Pacific region, and Latin America, for the commercialization of the Iberis® RDN system. According to the announcement, this system is currently the only renal denervation product approved globally with both transradial (TRA) and transfemoral (TFA) approaches.</p>\n<p>Biosensors is a Bermuda-incorporated company under the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (002382), operating worldwide with headquarters in Singapore and a European office in Morges, Switzerland.</p>\n<p>The announcement also states that there is no guarantee Iberis® RDN system will be ultimately developed or marketed successfully, and investors are advised to exercise due care when dealing in the shares of Shanghai Bio-heart Biological Technology Co., Ltd.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1181625029","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181625029","pubTimestamp":1761222226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"上海生物心脏(2185)公布Iberis首个商业案例®瑞士的RDN系统","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) reported that its subsidiary, Shanghai AngioCare Medical Technology Co., Ltd., recently completed the first commercial procedure using the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) in Switzerland. The procedure took place at the University Hospital Basel with no complications or adverse events reported, supported jointly by Biosensors International Group, Ltd. and AngioCare.\nAngioCare and Biosensors have a strategic partnership covering multiple regions, including the European Union, the Asia–Pacific region, and Latin America, for the commercialization of the Iberis® RDN system. According to the announcement, this system is currently the only renal denervation product approved globally with both transradial (TRA) and transfemoral (TFA) approaches.\nBiosensors is a Bermuda-incorporated company under the cardiovascular and cerebrovascular business division of Bule Sail Medical Co., Ltd. (002382), operating worldwide with headquarters in Singapore and a European office in Morges, Switzerland.\nThe announcement also states that there is no guarantee Iberis® RDN system will be ultimately developed or marketed successfully, and investors are advised to exercise due care when dealing in the shares of Shanghai Bio-heart Biological Technology Co., Ltd.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}